Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Amylyx Pharmaceuticals
Biotech
Amylyx stock slips 6% after phase 2 rare disease data drop
After Relyvrio’s market withdrawal, Amylyx is sharing early phase 2 data in a separate rare disease.
Gabrielle Masson
Apr 10, 2024 2:48pm
Seelos' sugar therapy fails to improve ALS severity in ph. 2/3
Mar 19, 2024 10:00am
FDA promotes Bumpus to replace Woodcock—Chutes & Ladders
Dec 1, 2023 9:48am
BrainStorm asks for ALS approval 1 year after FDA spiked data
Aug 15, 2022 12:28pm
Good news or bad news? FDA delays decision for Amylyx's ALS drug
Jun 3, 2022 10:25am
Amylyx's ALS drug voted down by FDA advisory committee
Mar 30, 2022 5:50pm